SCHEMBL769872

SCHEMBL769872

COc1ccc(-n2cnc3cc(C(N)Cc4ccc(C(C)C)cc4)ccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
ALDH1A1 P00352 5/20 0.56
FGFR1 P11362 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 3/20 0.49
TP53 P04637 1/20 0.49
GSK3B P49841 1/20 0.48
KDR P35968 1/20 0.48
HTT P42858 3/20 0.48
HPGD P15428 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
GAA P10253 2/20 0.45
ALOX12 P18054 1/20 0.45
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15201290 0.84 FGFR1 (0.59) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL769873 0.82 MAPT (0.54) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL769761 0.80 NPC1 (0.64) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL769874 0.79 MAPT (0.51) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL15201869 0.78 ALDH1A1 (0.57) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL15201870 0.78 ALDH1A1 (0.57) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL770107 0.75 MAPT (0.50) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL19781278 0.74 KDR (0.58) MAPTALDH1A1FGFR1SMN1; SMN2TP53
SCHEMBL3346179 0.72 ALDH1A1 (1.00) MAPTALDH1A1FGFR1SMN1; SMN2LMNA
SCHEMBL29357610 0.72 FGFR1 (1.00) MAPTALDH1A1FGFR1SMN1; SMN2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 MAPT 2844/4885ALDH1A1 4456/4885FGFR1 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.